Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — Oppenheimer 34th Annual Healthcare Life Sciences Conference 2024
22 slides from Summit Therapeutics's conference presentation, Feb 15, 2024
Slide 1: Oppenheimer's 34th Annual Healthcare Life Sciences Conference
Oppenheimer’s 34th Annual Healthcare Life Sciences Conference Dr. Maky Zanganeh Bob Duggan CEO & President Chairman & CEO
Slide 2: Forward Looking Statement
Forward Looking Statement Ivonescimab is an investigational therapy that is not approved by any regulatory authority. It is currently being investigated in Phase III clinical studies. 2 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Oppenheimer 34th Annual Healthcare Life Sci
Slide 3: Company Details
Company Details Focus ONCOLOGY Partnership Akeso Inc. Summit License Territories United States, Canada, Europe, Japan Chief Executive Officers Bob Duggan Chairman & CEO Dr. Maky Zanganeh CEO & President NASDAQ SMMT Market Cap $3.15B† Cash $186M** Employees 110+† Offices Miami, FL Menlo Park, CA Oxfo
Slide 4: Partnership with Akeso: An Aligned Mission
Partnership with An Aligned Mission Bringing ivonescimab to patients around the world Summit is actively recruiting two Phase III NSCLC clinical trials LEADING BIOPHARMA COMPANY IN CHINA Michelle Xia, Ph.D. Co-Founder, Chairwoman, President and CEO Over 2,800 Employees End-to-end In-house Capabiliti
Slide 5: Shaping the Path to Become a Commercial Entity
Shaping the Path to Become a Commercial Entity SITC: Society for Immunotherapy of Cancer; MOA: Mechanism of Action; ASCO: American Society of Clinical Oncology; NSCLC: Non -small Cell Lung Cancer; EORTC: European Organisation for Research and Treatment of Cancer; NCI: National Cancer Institute; AACR
Slide 6: Ivonescimab: Mechanism of Action
Ivonescimab: Mechanism of Action
Slide 7: Designed to Potentially Improve the Balance of Anti-tumor Activity & Safety
Designed to Potentially Improve the Balance of Anti-tumor Activity & Safety1,2 *There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”). Ivonescimab is an investigational therapy that is not approved by an
Slide 8: Cooperative Binding Greater Than the Sum of Its Parts
VEGF Dimer PD-1 Receptor in T Cell Increased Avidity in TME VEGF increases affinity to PD-1 by >18X4 PD-1 increases affinity to VEGF by >4X4 (in vitro) Enhanced Activity of T Cells VEGF dimer leads to potential interconnection of ivonescimab molecules, which may increase activity of T cells4,5 Ivone
Slide 9: Ivonescimab clinical trials by indication and phase
Trial Indication Histology/Population Regimen Phase III NSCLC EGFRm+ 2L+ Advanced or Metastatic Combo ivonescimab + chemo vs. placebo + chemo NSCLC Squamous 1L Metastatic Combo ivonescimab + chemo vs. pembro + chemo Indication Regimen Phase I Phase II Phase III NSCLC: 2L EGFRm+ Randomized: Combo (ch
Slide 10: Ivonescimab Clinical Data
Ivonescimab Clinical Data
Slide 11: AK112-201 Cohort 1: Squamous NSCLC with chemo
AK112-201 Cohort 1: Squamous only; ivonescimab + chemo Phase II, N=63 ORR† 67% DCR† 95% mDOR† 12.8m mPFS [95% CI] 11.1m [9.5 – 16.3] KEYNOTE-407 China Extension4 pembrolizumab + chemo; randomized Phase III, N=65 KEYNOTE-407 Global5 pembrolizumab + chemo; randomized Phase III, N=278 ORR† 80% 63% DCR†
Slide 12: Overall survival in 1L squamous NSCLC
OS: overall survival, DCO: data cutoff NSCLC: Non-small Cell Lung Cancer, 1L: First Line, CI: Confidence Interval, SQ: Squamous, pembro: pembrolizumab, chemo: chemotherapy, NE: Not Established, NR Not Reached, TRAEs: Treatment Related Adverse Events Ivonescimab is an investigational therapy that is
Slide 13: EGFR-mutant NSCLC response and PFS comparison
MARIPOSA-24 amivantamab + chemo; randomized Phase III, N=131 KEYNOTE-7895 pembrolizumab + chemo; randomized Phase III, N=245 KEYNOTE-7895 placebo + chemo; randomized Phase III, N=247 ORR† [95% CI] 64.1% [55 – 72] 29.0% [23 – 35] 27.1% [22 – 33] mDOR 6.9m 6.3m 5.6m mPFS [95% CI] 6.3m [5.6 – 8.4] 5.6m
Slide 14: Overall Survival for EGFR-TKI Progressors
MARIPOSA-24 amivantamab + chemo; randomized Phase III, N=131 KEYNOTE-7895 pembrolizumab + chemo; randomized Phase III, N=245 KEYNOTE-7895 placebo + chemo; randomized Phase III, N=247 mOS NR 15.9m [13.7 – 18.8] 14.7m [12.7 – 17.1] 12m OS NR 62% 59% AK112-201 Cohort 2 (EGFR+) ivonescimab + chemo Phase
Slide 15: Ivonescimab Phase II Safety Data in Key NSCLC Settings
Ivonescimab Phase II Safety Data in Key NSCLC Settings Ivonescimab Demonstrated a Tolerable Safety Profile DCO: 10/10/2023 15 Number (%) Grade >3 TRAE 28 (44.4) TRAE leading to discontinuation of ivonescimab 7 (11.1) TRAE leading to death 0 Number (%) Grade >3 TRAE 7 (36.8) TRAE leading to discontin
Slide 16: Ivonescimab Opportunity
Ivonescimab Opportunity
Slide 17: No PD-1/VEGF bispecific antibodies approved or in Phase III in Summit's territories
There are no PD-1/VEGF bispecific antibodies approved or in Phase III in Summit’s license territories Approved Anti PD-(L)1 Therapies Approved Anti-VEGF Therapies There are 50+ Approved Indications for PD-(L)1 & VEGF Therapies Data from cancer.gov updated 2023 17 Summit Proprietary Information - Do
Slide 18: Focusing On High Unmet Needs – Near Term
Focusing On High Unmet Needs – Near Term * UK, Germany, France, Italy, Spain 1 American Cancer Society: www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html (Accessed Jan 2024); World Health Organization: International Agency for Research on Cancer, Globocan data by country (UK, Spain,
Slide 19: Ivonescimab: Expected 2024 Key Catalysts
Ivonescimab: Expected 2024 Key Catalysts
Slide 20: Ivonescimab Phase III Trials – Expected 2024 Short-Term Catalysts
Ivonescimab Phase III Trials – Expected 2024 Short-Term Catalysts Ivonescimab is an investigational therapy that is not approved by any regulatory authority. It is currently being investigated in Phase III clinical studies. CDE: Centre for Drug Evaluation *NDA Filing by Akeso with the CDE for Market
Slide 21: Summit Therapeutics
( Summit therapeutics
Slide 22: Q&A
lUlpalaalis therapeutics © Q&A ~—_ae
Summit Therapeutics — Oppenheimer 34th Annual Healthcare Life Sciences Conference 2024 on 6ix